217 unknown. 217 Phase 2, 25 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 217 | Unknown 217 |
| Phase 1 | 25 | Unknown 25 |
| Phase 3 | 8 | Unknown 8 |
Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer Adebrelimab + Apatinib + Lrinotecan liposome - Advanced Gastric Cancer | Phase 1 / Phase 2 | Unknown | Xianglin Yuan | 66 | 2024-09-30 | 2024-09-19 |
| A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation Camrelizumab, Apatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Zhujiang Hospital | 38 | 2024-08-26 | 2024-08-09 |
| Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC) - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Henan University of Science and Technology | 54 | 2024-07-15 | 2024-06-18 |
| HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 33 | 2024-06-19 | 2024-07-01 |
| Tucidinostat Plus Apatinib for Advanced Osteosarcoma Tucidinostat, Apatinib - Osteosarcoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 46 | 2024-01-01 | 2023-11-09 |
| Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma camrelizumab and apatinib - Chordoma, Chemotherapy Effect | Phase 2 | Unknown | Xuanwu Hospital, Beijing | 30 | 2023-10-30 | 2023-11-20 |
| Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab - NSCLC, Non-small Cell Lung Cancer | Phase 2 | Unknown | Sun Yat-sen University | 60 | 2023-07-01 | 2023-07-06 |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma adebrelimab, camrelizumab plus apatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 52 | 2023-07-01 | 2024-02-21 |
| HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma HAIC Combined with Tislelizumab and Apatinib - Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Binkui Li | 17 | 2023-05-31 | 2023-04-13 |
| A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC HAIC, Camrelizumab plus Apatinib - Macrotrabecular Massive Hepatocellular Carcinoma | Phase 2 | Unknown | Wan-Guang Zhang | 38 | 2023-05-05 | 2023-12-19 |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer AK104, Apatinib, Paclitaxel - Gastric Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2023-03-21 | 2023-05-10 |
| A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs Anti-PD-1 monoclonal antibody, VEGFR2 Tyrosine Kinase Inhibitor - Breast Cancer, Triple-Negative Breast Cancer | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 58 | 2022-12-01 | 2023-04-12 |
| Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer Fluzopari and apatinib - Ovarian Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 35 | 2022-11-01 | 2022-10-28 |
| Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Apatinib, Camrelizumab, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel) - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 84 | 2022-10-08 | 2023-02-08 |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Azacitidine Injection, Dasatinib, Linperlisib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 116 | 2022-09-30 | 2022-11-09 |
| HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma HAIC Combined with Tislelizumab and Apatinib - Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Yunfei Yuan | 17 | 2022-07-21 | 2022-08-05 |
| mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC mFOLFOX7+Camrelizumab+Apatinib - Stage III Hepatocellular Cancer (CNLC Staging) | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 35 | 2022-06-10 | 2024-07-31 |
| Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer Camrelizumab, Apatinib Mesylate - Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 68 | 2022-05-01 | 2022-04-22 |
| SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy Camrelizumab, Apatinib, Docetaxel injection - Non-Small Cell Lung Cancer | Phase 2 | Unknown | Wuhan University | 88 | 2022-03-15 | 2022-05-02 |
| A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W) - Gastric Cancer, Chemotherapy | Phase 2 | Unknown | Jiuda Zhao | 31 | 2022-02-15 | 2022-04-11 |
Showing 20 of 217. Sign in to see all of them.
Stomach Neoplasms (22) · Carcinoma, Hepatocellular (18) · Carcinoma, Non-Small-Cell Lung (12) · Colorectal Neoplasms (12) · Small Cell Lung Carcinoma (9) · Ovarian Neoplasms (8) · Sarcoma (8) · Lung Neoplasms (7) · Nasopharyngeal Carcinoma (7) · Breast Neoplasms (6) · Head and Neck Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Cholangiocarcinoma (4) · Esophageal Neoplasms (4) · Esophageal Squamous Cell Carcinoma (4)
Sun Yat-sen University (15) · Tianjin Medical University Cancer Institute and Hospital (13) · Henan Cancer Hospital (12) · Chinese Academy of Medical Sciences (8) · Fujian Cancer Hospital (8) · Fudan University (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Chinese PLA General Hospital (5) · Shanghai Zhongshan Hospital (5) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5) · Anhui Provincial Hospital (4) · Hebei Medical University (4) · Peking University Cancer Hospital & Institute (4) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (4) · Sichuan Cancer Hospital and Research Institute (4)
China (176)
Binghe Xu (2) · Li Xiao, Doctor (2) · Wei Deng, M.D. (2) · Xiaohui He, B.D. (2) · YunPeng Liu, PhD (2) · Baorui Baorui Liu, Doctor (1) · Caicun Zhou (1) · Caicun Zhou, MD,PhD (1) · Chengxue Dang, PhD (1) · Chenping Zhang, M.D. (1) · CongHua Xie, MD (1) · Da Zhao, Bachelor (1) · Daiyuan Ma, M.D (1) · Desheng Hu (1)
PMID 26884585, PMID 18172173, PMID 18971936, PMID 21183517, PMID 21296855, PMID 21742485, PMID 23918952, PMID 37580352, PMID 19331206, PMID 20923544, PMID 23464465, PMID 23510598, PMID 24024839, PMID 24140268, PMID 24307987, PMID 24472472, PMID 24484722, PMID 24500024, PMID 24511038, PMID 24950987, PMID 25299232, PMID 25862517, PMID 26341920, PMID 26755520, PMID 29245310, PMID 30026059, PMID 30348638, PMID 31261514, PMID 31401903, PMID 32250517, PMID 32448335, PMID 32719455, PMID 32827353, PMID 33145266, PMID 33178765, PMID 33187916, PMID 33209881, PMID 33314747, PMID 33995600, PMID 34043812, PMID 34409776, PMID 34484431, PMID 34515993, PMID 34540013, PMID 34540697, PMID 34858178, PMID 35105939, PMID 35190519, PMID 35280426, PMID 35282086